March 29, 2012
/PRNewswire/ --ChromaDex Corporation (OTCBB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries, announced today it has retained RJ Palmer as its media planning and buying agency for a national advertising and media campaign for
), its recently launched line of dietary supplements.
The multimillion dollar national media spend will include television, radio and digital outlets. The television and radio campaigns were produced by the award-winning Alcone Marketing Group. The radio campaign began in early March, and the television campaign began this week.
line is currently comprised of:
The nationwide launch of
in retail outlets began in earnest early this year. During the month of January,
became available at a national drug store chain with more than 8,000 stores in the U.S., as well as at approximately 4,000 independent drugstores and pharmacies in the U.S. through a distribution agreement with one of the largest pharmaceutical distributors in
is also available at a prominent online retailer, as well as a national health and nutrition products retailer. It is expected that
will be available in more than 25,000 retail stores by year-end 2012, as well as through major online retailers.
The novel ingredient in
is ChromaDex's proprietary, patent-pending pterostilbene, branded as
), which was named the
2010 North American Most Promising Ingredient of the Year
by the independent research company, Frost & Sullivan.
is a proprietary, nature-identical formulation of the compound pterostilbene, which is found naturally in blueberries. Pterostilbene has superior biological activity, better oral bioavailability and metabolizes more slowly in the body than other polyphenols (phytochemicals with antioxidant activities that help fight free radicals), allowing more time for its antioxidant activities to act. However, the amount of pterostilbene present in a typical serving of blueberries is a tiny fraction of the amount needed to realize its benefits. In fact, one BluScience
capsule has the equivalent amount of pterostilbene as contained in more than 500 cartons of blueberries.
About RJ Palmer:
RJ Palmer (
) is a full service media agency headquartered in
New York City
with billings in excess of
. It is a subsidiary of holding company, MDC Partners. Palmer provides strategic insights, TV, Print, OOH, Radio and Online media planning and buying as well as Corporate Barter and Branded Entertainment.
About Alcone Marketing Group:
Alcone Marketing Group is a leading Activation and Integrated Marketing agency with offices in
San Francisco, CA
. Alcone is part of Omnicom Group Inc. (NYSE: OMC).
About Omnicom Group:
Omnicom Group Inc. (NYSE: OMC) (
) is a leading global marketing and corporate communications company. Omnicom's branded networks and numerous specialty firms provide advertising, strategic media planning and buying, digital and interactive marketing, direct and promotional marketing, public relations and other specialty communications services to over 5,000 clients in more than 100 countries.
ChromaDex, Inc. is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries. The company has an expanding pipeline of new ingredients, including its
) pterostilbene for which it has worldwide, exclusive patent pending rights. The company recently launched its
line of dietary supplements. Capitalizing on the diverse potential applications of the product, ChromaDex is also developing pTeroPure
for the skincare and pharmaceutical markets, among others. pTeroPure
is currently being studied in a human clinical trial at the
University of Mississippi
. For more information about pTeroPure
or call 949-600-9694.
Any statements that are not historical facts contained in this release are "forward-looking statements" as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in the companies' filings with the Securities and Exchange Commission, and risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the companies do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.
ChromaDex Investor Contact:
Liviakis Financial Communications, Inc.
John M. Liviakis
, President 415-389-4670
Institutions and Analysts Contact:
The Del Mar Consulting Group, Inc.
Robert B. Prag
SOURCE ChromaDex Corporation